Beihai Gofar Chuanshan Biological Co., Ltd. (SHA:600538)
China · Delayed Price · Currency is CNY 6.72
-0.13 (-1.90%)
Apr 30, 2026, 3:00 PM CST
SHA:600538 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 325.54 | 338.3 | 367.06 | 457.25 | 421.98 |
Other Revenue | 2.7 | 2.16 | 2.09 | 2.44 | 2.73 |
| 328.24 | 340.47 | 369.15 | 459.68 | 424.72 | |
Revenue Growth (YoY) | -3.59% | -7.77% | -19.69% | 8.23% | 58.65% |
Cost of Revenue | 261.32 | 254.68 | 279.46 | 332.98 | 316.59 |
Gross Profit | 66.92 | 85.78 | 89.7 | 126.71 | 108.12 |
Selling, General & Admin | 87.01 | 86.58 | 90.44 | 85.93 | 83.08 |
Research & Development | 7.23 | 8.06 | 12.62 | 8.22 | 9.14 |
Other Operating Expenses | 2.9 | 2.95 | 3.33 | 3.17 | 3.67 |
Operating Expenses | 96.28 | 101 | 111.05 | 102.18 | 98.71 |
Operating Income | -29.36 | -15.21 | -21.35 | 24.53 | 9.42 |
Interest Expense | -2.43 | -2.34 | -0.37 | -0.51 | -0.53 |
Interest & Investment Income | 14.46 | 2.63 | 3.58 | 17.38 | 4 |
Currency Exchange Gain (Loss) | 0.09 | -0.05 | -0.07 | -0.35 | 0.71 |
Other Non Operating Income (Expenses) | -2.41 | -3.23 | -1.59 | -0.51 | 0.1 |
EBT Excluding Unusual Items | -19.65 | -18.2 | -19.8 | 40.54 | 13.7 |
Impairment of Goodwill | -61.86 | -60.21 | -55.43 | - | - |
Gain (Loss) on Sale of Investments | 0.29 | -11.34 | -2.66 | -0.27 | -0.85 |
Gain (Loss) on Sale of Assets | -0.09 | -2.71 | -0.08 | 0.07 | -0.02 |
Asset Writedown | -3.73 | - | -1.4 | - | -0.41 |
Other Unusual Items | 0.29 | 0.47 | 1.81 | 1.76 | 3.36 |
Pretax Income | -84.76 | -91.98 | -77.57 | 42.11 | 15.79 |
Income Tax Expense | 1.86 | -0.07 | 3.59 | 5.46 | 5.86 |
Earnings From Continuing Operations | -86.62 | -91.91 | -81.16 | 36.65 | 9.93 |
Net Income to Company | -86.62 | -91.91 | -81.16 | 36.65 | 9.93 |
Minority Interest in Earnings | -1 | -1.94 | -1.15 | -1.81 | 0.56 |
Net Income | -87.62 | -93.85 | -82.31 | 34.84 | 10.49 |
Net Income to Common | -87.62 | -93.85 | -82.31 | 34.84 | 10.49 |
Net Income Growth | - | - | - | 232.25% | 227.65% |
Shares Outstanding (Basic) | 515 | 521 | 514 | 498 | 524 |
Shares Outstanding (Diluted) | 515 | 521 | 514 | 498 | 524 |
Shares Change (YoY) | -1.15% | 1.35% | 3.35% | -5.07% | 14.68% |
EPS (Basic) | -0.17 | -0.18 | -0.16 | 0.07 | 0.02 |
EPS (Diluted) | -0.17 | -0.18 | -0.16 | 0.07 | 0.02 |
EPS Growth | - | - | - | 250.00% | 185.71% |
Free Cash Flow | -19.86 | -8.12 | -28 | -23.51 | -29.63 |
Free Cash Flow Per Share | -0.04 | -0.02 | -0.05 | -0.05 | -0.06 |
Gross Margin | 20.39% | 25.20% | 24.30% | 27.56% | 25.46% |
Operating Margin | -8.95% | -4.47% | -5.79% | 5.34% | 2.22% |
Profit Margin | -26.69% | -27.57% | -22.30% | 7.58% | 2.47% |
Free Cash Flow Margin | -6.05% | -2.38% | -7.58% | -5.11% | -6.98% |
EBITDA | -15.83 | -1.59 | -7.47 | 37.55 | 22.44 |
EBITDA Margin | -4.82% | -0.47% | -2.02% | 8.17% | 5.28% |
D&A For EBITDA | 13.54 | 13.62 | 13.88 | 13.02 | 13.02 |
EBIT | -29.36 | -15.21 | -21.35 | 24.53 | 9.42 |
EBIT Margin | -8.95% | -4.47% | -5.79% | 5.34% | 2.22% |
Effective Tax Rate | - | - | - | 12.97% | 37.13% |
Revenue as Reported | 328.24 | 340.47 | 369.15 | 459.68 | 424.72 |
Advertising Expenses | 0.78 | 2.97 | 2.2 | 1.04 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.